Teaming agreement positions Attune’s pipeline for immediate Strategic National Stockpile readiness while unlocking up to $75 million in shared revenue.
Callan JMB Inc. has signed a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech Inc., creating a partnership designed to fast-track federal deployment of critical medical countermeasures. The agreement leverages Callan JMB’s deep experience in federal contracting, cold chain logistics, and Strategic National Stockpile (SNS) operations to provide Attune with immediate operational readiness—bypassing the multi-year setup timelines typically required for new pharmaceutical platforms.
Under the agreement, Callan JMB will act as an independent third-party overseer across Attune’s manufacturing, quality assurance, and deployment activities. Services include BARDA contract compliance, FDA audit readiness and mock inspections, independent batch record review, supplier qualification, milestone tracking, and coordination for SNS deployment. This comprehensive oversight framework positions Attune’s pipeline for rapid federal procurement and distribution using Callan JMB’s existing infrastructure with BARDA, the Department of Defense, the Department of Veterans Affairs, and the Strategic National Stockpile.
The partnership builds on a successful surge-readiness simulation completed in late 2024, in which Attune and Callan JMB’s subsidiary Coldchain Technology Services replicated a 500,000-unit deployment across six regional SNS sites. The exercise met federal benchmarks for 10-day activation while validating compliance with DSCSA, GDP, and DEA requirements. The platform is now qualified for 24-hour emergency activation and nationwide distribution within 48 hours.
Financially, the companies anticipate generating $50 million to $75 million in combined revenue over the next five years, with Callan JMB’s share estimated at $25 million to $45 million through a structured profit-sharing model.
With Attune’s therapies targeting unmet needs in pandemic preparedness, veteran health, and emergency response, the alliance significantly accelerates its path to federal deployment. For Callan JMB, the agreement represents a meaningful expansion of its role in the U.S. medical countermeasure ecosystem—where speed, compliance, and reliability are critical to national readiness.
You might like this article:Springview Holdings Explores Solar Integration Through Strategic Green-Energy Partnership
